Further Milestone Payment Under Novartis Collaboration as Kisqali® (ribociclib) Receives FDA approval as a First-Line Treatment for HR+/HER2- Advanced Breast Cancer with an aromatase inhibitor Novartis drug Kisqali® (ribociclib, LEE011) receives marketing approval by the US FDA as a first-line drug for HR+/HER2- advanced breast cancer in combination with an aromatase inhibitor Astex’s scientific expertise […]
About Peggy Bickerton
This author has yet to write their bio.Meanwhile lets just say that we are proud Peggy Bickerton contributed a whooping 2 entries.
Entries by Peggy Bickerton
2-6 June 2017 Chicago, IL visit conference website